case_images: PMC6349975_01
case_images: Testosterone values measured prior to each injection (trough values) returned to the normal range right after the first treatment and remained at that level onward.
case_images: 10.1177_2050313X18823454-fig1.jpg
case_images: PMC6349975_01_10.1177_2050313X18823454-fig1.jpg
case_images: fig1-2050313X18823454
case_images: Right after the first injection, testosterone returned to the normal range and remained at that level throughout the observation time (Figure 1).
case_images: (a) Significant overweight at baseline was reduced to nearly normal weight within the first 4 years of TTh and weight reduction then maintained onward; (b) a BMI of originally 28.4 kg/m2 was reduced to 25 kg/m2 within the first 4 years of TTh.
case_images: 10.1177_2050313X18823454-fig2.jpg
case_images: PMC6349975_01_10.1177_2050313X18823454-fig2.jpg
case_images: fig2-2050313X18823454
case_images: TTh, the patient constantly lost weight (-10 kg) and waist circumference was reduced by 8 cm, resulting in a BMI of 25 kg/m2 (Figure 2(a) and (b)). The weight loss was sustained throughout the observation time, that is, the patient did not regain weight during the following years.
case_images: HbA1c decreased from 7.2% (baseline) to below 6.5% from month 21 onward; fasting blood glucose decreased from 6.6 to 6.0 mmol/L after month 3 and remained below this value onward; HOMA-IR decreased from 8.5 to 2.5 at month 66 (last measurement).
case_images: 10.1177_2050313X18823454-fig3.jpg
case_images: PMC6349975_01_10.1177_2050313X18823454-fig3.jpg
case_images: fig3-2050313X18823454
case_images: Under TTh blood glucose level and lipid profile normalized progressively, HbA1c remained below 6.5% from month 21 onward and below 5.7% from month 36 onward; fasting blood glucose decreased to 6.0 mmol/L after 3 months, to below 5.7 mmol/L after 12 months, and then remained permanently below this value; insulin resistance constantly improved (HOMA-IR: 3.9 at month 24; Figure 3); serum lipid levels dropped back to normal (LDL/HDL ratio < 3 and triglycerides <= 2.5 mmol/L from month 30 onward; Figure 4(a) and (b)).
case_images: (a) The LDL/HDL ratio decreased from 5.4 (baseline) to below 3 from month 30 onward; (b) triglycerides decreased from 3.0 mmol/L (baseline) to below 2.5 mmol/L from month 42 onward.
case_images: 10.1177_2050313X18823454-fig4.jpg
case_images: PMC6349975_01_10.1177_2050313X18823454-fig4.jpg
case_images: fig4-2050313X18823454
case_images: Under TTh blood glucose level and lipid profile normalized progressively, HbA1c remained below 6.5% from month 21 onward and below 5.7% from month 36 onward; fasting blood glucose decreased to 6.0 mmol/L after 3 months, to below 5.7 mmol/L after 12 months, and then remained permanently below this value; insulin resistance constantly improved (HOMA-IR: 3.9 at month 24; Figure 3); serum lipid levels dropped back to normal (LDL/HDL ratio < 3 and triglycerides <= 2.5 mmol/L from month 30 onward; Figure 4(a) and (b)).
case_images: Blood pressure of 176/118 mmHg at baseline normalized to 137/84 mm Hg at month 30.
case_images: 10.1177_2050313X18823454-fig5.jpg
case_images: PMC6349975_01_10.1177_2050313X18823454-fig5.jpg
case_images: fig5-2050313X18823454
case_images: A high blood pressure of originally 176/118 mmHg despite prescription of anti-hypertensive drugs decreased to 137/84 mmHg at month 30 (Figure 5).